Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

Summary

ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years
* Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
* In neo-adjuvant, adjuvant, recurrence or metastatic situation
* Suffering from solid tumor histologically documented
* Signed written informed consent
* Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion.

Exclusion Criteria:

* Pregnant or breastfeeding women
* Patient already treated by immunotherapy by immune checkpoint inhibitor
* Person under guardianship
* Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)

Conditions2

Browse More Trials